RTW leans into NewCo model with GenSci deal for ocular autoimmune therapy: Deals Report

RTW Investments has made a deal with China-based GenSci for most global rights to a TSHR-targeting mAb to treat ocular autoimmune disorders, using the NewCo model to create a start-up that will advance the program.

The firm has backed Yarrow Bioscience Inc. with an undisclosed amount of capital to advance clinical molecule GS-098 from Changchun GeneScience Pharmaceutical Co. Ltd. to treat Graves disease and thyroid eye disease (TED). RTW said it is paying $70 million up front for rights outside China to the therapy, which will also be known as YB-101. The deal includes a $50 million near-term milestone and a total value of nearly $1.4 billion, plus royalties...